Drs. Kuykendall and Hobbs discuss the latest MPN updates, with a look ahead to ASCO® 2025
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Drs. Kuykendall and Hobbs discuss the latest MPN updates, with a look ahead to ASCO® 2025
-
Narrated by:
-
By:
About this listen
Andrew Kuykendall, MD, of Moffitt Cancer Center in Tampa, Florida hosts a podcast on the latest news in myeloproliferative neoplasms (MPNs) with guest Gabriela Hobbs, MD, of Massachusetts General Research Institute.
The pair discuss treatment goals for patients with MPNs, especially as treatments evolve and become more targeted for treatment.
“As therapies get better, we can offer more to our patients,” Dr. Hobbs said.
One upcoming abstract of interest at ASCO® 2025 includes Dr. Kuykendall’s oral abstract, titled “Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV),” which will be available for attendees on June 1, 2025, the ASCO® 2025 website.
They also discussed patients’ heart risks and pulmonary hypertension, needing teamwork with other doctors.
“We really need to strengthen those relationships with other specialties,” Dr. Kuykendall said.